Humanigen CEO says company is developing drug to make 'the new frontier' in cancer therapy safer

Humanigen CEO speaks with OTC Markets about strategy to optimize CAR-T therapy

Cure Brain Cancer Foundation (Australia) highlights ifabotuzumab clinical trial for GBM

Immunotherapy: the promise and perils of a new generation of cancer treatments (STAT Ebook)

Axicabtagene Ciloleucel CAR T-Cell Therapy Paper Notes GM-CSF as Biomarker Significantly Associated with Neurotoxicity

Cancer researchers learn more about toxic side effects of new treatments